StageZero Life Sciences Ltd
TSX:SZLS

Watchlist Manager
StageZero Life Sciences Ltd Logo
StageZero Life Sciences Ltd
TSX:SZLS
Watchlist
Price: 0.04 CAD
Market Cap: 4.9m CAD

StageZero Life Sciences Ltd
Change in Working Capital

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

StageZero Life Sciences Ltd
Change in Working Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Change in Working Capital CAGR 3Y CAGR 5Y CAGR 10Y
StageZero Life Sciences Ltd
TSX:SZLS
Change in Working Capital
-$836.4k
CAGR 3-Years
N/A
CAGR 5-Years
-13%
CAGR 10-Years
6%
Theratechnologies Inc
TSX:TH
Change in Working Capital
-$5.7m
CAGR 3-Years
N/A
CAGR 5-Years
-64%
CAGR 10-Years
N/A
Repare Therapeutics Inc
NASDAQ:RPTX
Change in Working Capital
-$4.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Change in Working Capital
$7.2m
CAGR 3-Years
N/A
CAGR 5-Years
76%
CAGR 10-Years
12%
X
Xenon Pharmaceuticals Inc
NASDAQ:XENE
Change in Working Capital
-$2.4m
CAGR 3-Years
-49%
CAGR 5-Years
N/A
CAGR 10-Years
17%
Spectral Medical Inc
TSX:EDT
Change in Working Capital
CA$160k
CAGR 3-Years
13%
CAGR 5-Years
-53%
CAGR 10-Years
-7%
No Stocks Found

StageZero Life Sciences Ltd
Glance View

Market Cap
4.9m CAD
Industry
Biotechnology

StageZero Life Sciences Ltd. engages in the development and commercialization of proprietary molecular diagnostic tests for detection of diseases and for personalized health management, with a focus on cancer-related indications. The company is headquartered in Richmond Hill, Ontario and currently employs 80 full-time employees. The firm has developed Sentinel Principle platform technology, which determines biomarkers from whole blood. The firm offers ColonSentry product, which is a blood test to determine an individual’s current risk for having colorectal cancer. The company offers Aristotle, a mRNA-based multi-cancer detection panel for simultaneously screening of various cancers from a single sample of blood. In addition, the Company offers various COVID-19 tests, including polymerase chain reaction (PCR) tests and antibody tests. Its PCR tests can detect COVID-19 nucleic acid from patient nasopharyngeal swab specimens or saliva and are used to diagnose an active COVID-19 infection.

SZLS Intrinsic Value
0.05 CAD
Undervaluation 18%
Intrinsic Value
Price

See Also

What is StageZero Life Sciences Ltd's Change in Working Capital?
Change in Working Capital
-836.4k USD

Based on the financial report for Sep 30, 2024, StageZero Life Sciences Ltd's Change in Working Capital amounts to -836.4k USD.

What is StageZero Life Sciences Ltd's Change in Working Capital growth rate?
Change in Working Capital CAGR 10Y
6%

Back to Top